Family Medicine Doctors in Morton, MS Accepting Medicare
3 Family Medicine doctors found. Showing 1 - 3
 Christine S Peddapanga, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 321 Highway 13 S, Morton, MS 39117 Phone: 601-732-8612 Fax: 601-732-1957 |
Kimberly Jane Mckay, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 317 Highway 13 S, Morton, MS 39117 Phone: 601-732-6301 Fax: 601-732-1062 |
Nahid Islam, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 321 Highway 13 S, Morton, MS 39117 Phone: 601-732-8612 |
News Archive
Anti-inflammatory drug ibuprofen may fight against certain cancers
Latest research by scientists at the University of Bath has shown why the anti-inflammatory drug ibuprofen might stop certain cancers from developing.
Research aims to describe women's experience of living with MS
The women who I asked would like to have time and opportunity to express grief and vulnerability in contact with health services. They also expect a response based on their individual situation and needs, "said Malin Olsson, Ph.D. at Luleå University of Technology.
Transgenomic awarded $1,070,453 grant under Patient Protection and Affordable Care Act
Transgenomic, Inc. today announced that it has been awarded a research and development grant totaling $1,070,453.32 from the U.S. government under HR: 3590 – Patient Protection and Affordable Care Act (the "Act") in immediately available funds. This is among the largest awards for any one company under the Act.
Roche's MabThera continues to dwarf recently launched monoclonal antibodies: Report
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
› Verified 2 days ago